PETRICHOR SCION THERAPEUTICS — Full Portfolio
2 tracked investments · listed companies and verified rows first
Avalo is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases.
BiotechMedical DevicesBaltimore, US
Mariam Morris(Executive Officer)Ronald Marcus(Executive Officer)Uli Hacksell(Executive Officer, Director)John Kaiser(Executive Officer)James Vornov(Executive Officer)Blake M. Paterson(Executive Officer, Director)
Board seatAaron Kantoff· per SEC Form D · $200M raise · filed Apr 2024
Co-investorsNew Enterprise Associates (NEA)OrbiMed
New York, US
Board seatAaron Kantoff· per SEC Form D · $50M raise · filed Jun 2017
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.